FDA Inspection 1193412 — Nephron Pharmaceuticals
The FDA completed an inspection of Nephron Pharmaceuticals on Dec 2, 2022 in Murray, KY. The inspection was classified VAI (Voluntary Action Indicated — objectionable conditions or practices were found, but the agency is not prepared to take or recommend any administrative or regulatory action). Product area: Drugs.
Inspection Details
- Classification
- Voluntary Action Indicated (VAI)
- End Date
- Dec 2, 2022
- Fiscal Year
- 2023
- Product Type
- Drugs
- Project Area
- Drug Quality Assurance
- Location
- Murray, KY (United States)